Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Niagen Bioscience, Inc.CDXC · Entity 6146 | Director | June 17, 2021 | June 22, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Niagen Bioscience, Inc.
Report date June 17, 2021 · Filed June 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.99 · Expires 2031-06-16 | Direct | 20,000 |
Reported balance
After 2021-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-17 · Grant · Acquired 20,000 · Balance 20,000 F1: Options vest 100% on June 17, 2022 |
Filing footnotes · ownership attribution and instrument terms
F1: Options vest 100% on June 17, 2022
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SENOMYX INC
Report date November 02, 2018 · Filed November 02, 2018
Section 16 reporting ended · disclosed 2018-11-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-11-02 transaction · row 1
1 source rowRow 1 · 2018-11-02 · Other · Disposed 1,000 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any applicable withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.90 · Expires 2027-05-10 | Direct | 0 |
Reported balance
After 2018-11-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-11-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2028-05-23 | Direct | 0 |
Reported balance
After 2018-11-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-11-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any applicable withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger").
F2: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2021 Filed Jun 22, 2021 17:25 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $9.99 | $0.00 |
DisclosureSEC source: 0001628280-21-012669 · wf-form4_162439709292333.xml · derivative · entry 1 BLOCK STEPHEN A · CIK 0001183721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-16 F1 · derivative.exercise_date: Options vest 100% on June 17, 2022 Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 18:41 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001415889-21-001545 · form4-03172021_030350.xml · derivative · entry 6 BLOCK STEPHEN A · CIK 0001183721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options were granted on November 16, 2016 and 100% vested on November 16, 2017. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 18:41 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | SaleCommon Stock | 20,000 | $13.17 | $263,400.00 |
DisclosureSEC source: 0001415889-21-001545 · form4-03172021_030350.xml · nonDerivative · entry 4 BLOCK STEPHEN A · CIK 0001183721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 F2 · price: The weighted average sale price for the transaction reported was $13.17, and the range of prices were between $13.10 and $13.34. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 18:41 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionCommon Stock | 20,000 | $2.61 | $52,100.00 |
DisclosureSEC source: 0001415889-21-001545 · form4-03172021_030350.xml · nonDerivative · entry 3 BLOCK STEPHEN A · CIK 0001183721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 18:41 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionStock Options (right to buy) · Derivative | 32,500 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001415889-21-001545 · form4-03172021_030350.xml · derivative · entry 5 BLOCK STEPHEN A · CIK 0001183721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,500 shares Expires 2022-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Options were granted on August 28, 2012 and vested 1/12th monthly from the grant date. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 18:41 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | SaleCommon Stock | 32,500 | $11.15 | $362,375.00 |
DisclosureSEC source: 0001415889-21-001545 · form4-03172021_030350.xml · nonDerivative · entry 2 BLOCK STEPHEN A · CIK 0001183721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 F1 · price: The weighted average sale price for the transaction reported was $11.15, and the range of prices were between $11.10 and $11.25. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 18:41 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionCommon Stock | 32,500 | $1.92 | $62,400.00 |
DisclosureSEC source: 0001415889-21-001545 · form4-03172021_030350.xml · nonDerivative · entry 1 BLOCK STEPHEN A · CIK 0001183721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2020 Filed Jun 22, 2020 21:16 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0001415889-20-001661 · form4-06222020_060609.xml · derivative · entry 1 BLOCK STEPHEN A · CIK 0001183721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-18 F1 · derivative.exercise_date: Options vest 100% on June 19, 2021. Read SEC document |
| June 21, 2019 Filed Jun 24, 2019 20:40 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-19-000798 · form4-06242019_050637.xml · derivative · entry 1 BLOCK STEPHEN A · CIK 0001183721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-06-21 F1 · derivative.exercise_date: Options vest 100% on June 21, 2020. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 20:42 UTC | Niagen Bioscience, Inc. CDXC.OB · Entity 6146 | Exercise / conversionStock Options (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-19-000306 · form4-03122019_050306.xml · derivative · entry 3 BLOCK STEPHEN A · CIK 0001183721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2019-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 20:42 UTC | Niagen Bioscience, Inc. CDXC.OB · Entity 6146 | SaleCommon Stock | 10,000 | $3.52 | $35,200.00 |
DisclosureSEC source: 0001415889-19-000306 · form4-03122019_050306.xml · nonDerivative · entry 2 BLOCK STEPHEN A · CIK 0001183721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 F2 · price: The weighted average sale price for the transaction reported was $3.52, and the range of prices were between $3.50 and $3.56. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. F1 · acquired: The options exercised and sold were scheduled to expire on May 13, 2019. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 20:42 UTC | Niagen Bioscience, Inc. CDXC.OB · Entity 6146 | Exercise / conversionCommon Stock | 10,000 | $1.50 | $15,000.00 |
DisclosureSEC source: 0001415889-19-000306 · form4-03122019_050306.xml · nonDerivative · entry 1 BLOCK STEPHEN A · CIK 0001183721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 18:04 UTC | SENOMYX INC SNMX · Entity 162645 | Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $1.36 | Not disclosed |
DisclosureSEC source: 0001209191-18-056992 · doc4.xml · derivative · entry 3 BLOCK STEPHEN A · CIK 0001183721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2028-05-23 F2 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F2 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 18:04 UTC | SENOMYX INC SNMX · Entity 162645 | Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $0.90 | Not disclosed |
DisclosureSEC source: 0001209191-18-056992 · doc4.xml · derivative · entry 2 BLOCK STEPHEN A · CIK 0001183721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2027-05-10 F2 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F2 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 18:04 UTC | SENOMYX INC SNMX · Entity 162645 | OtherCommon Stock | 1,000 | $1.50 | $1,500.00 |
DisclosureSEC source: 0001209191-18-056992 · doc4.xml · nonDerivative · entry 1 BLOCK STEPHEN A · CIK 0001183721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any applicable withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 17:08 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0001415889-18-001028 · form4-06262018_020648.xml · derivative · entry 1 BLOCK STEPHEN A · CIK 0001183721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-22 F1 · derivative.exercise_date: Options vest 100% on June 22, 2019. Read SEC document |
| May 24, 2018 Filed May 25, 2018 17:09 UTC | SENOMYX INC SNMX · Entity 162645 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001437749-18-010757 · rdgdoc.xml · derivative · entry 1 BLOCK STEPHEN A · CIK 0001183721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-05-23 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments beginning one month following the Date of Grant (5/24/2018). F2 · balance_after: The Reporting Person also holds outstanding options to purchase 115,639 shares of Common Stock. In addition, the Reporting Person beneficially owns 1,000 shares of common stock. Read SEC document |
| June 20, 2017 Filed Jul 3, 2017 17:16 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001415889-17-001085 · form4-07032017_020750.xml · derivative · entry 1 BLOCK STEPHEN A · CIK 0001183721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-06-20 F1 · derivative.exercise_date: Options vest 100% on June 20, 2018. Read SEC document |
| May 11, 2017 Filed May 22, 2017 18:23 UTC | SENOMYX INC SNMX · Entity 162645 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001437749-17-009848 · rdgdoc.xml · derivative · entry 1 BLOCK STEPHEN A · CIK 0001183721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-10 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments beginning one month following the Date of Grant (5/11/2017). Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 16:37 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001415889-16-007476 · form4-11182016_011151.xml · derivative · entry 1 BLOCK STEPHEN A · CIK 0001183721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-11-16 F1 · derivative.exercise_date: Options vest 100% on November 16, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.